Literature DB >> 21526069

Pulmonary alveolar proteinosis in children: a case series.

Seyyed Ahmad Tabatabaei1, Abdollah Karimi, Sedigheh Rafiee Tabatabaei, Badiozzaman Radpay, Farzaneh Jadali, Farideh Shiva, Mana Hadipour Jahromy.   

Abstract

Pulmonary alveolar proteinosis, (PAP) is a rare disease of unknown etiology, characterized by accumulation of intraalveolar proteinaceous material which is rich in lipid and positive on periodic acid-Schiff stain. Two clinically different pediatric types have been defined as congenital PAP which is fulminant and fatal, and a late-onset PAP which is similar to the adult form and less severe. Eight children with late-onset PAP were hospitalized from 1998 to 2005 in Mofid Children Hospital. Characteristics of these patients and the methods of diagnosis and treatment are presented in this case series.

Entities:  

Keywords:  Children; Pulmonary Alveolar Proteinosis; Respiratory Distress; Respiratory Failure

Year:  2010        PMID: 21526069      PMCID: PMC3082791     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


Pulmonary Alveolar Proteinosis (PAP) first described by Rosen et al in 1958.1 PAP is a rare disease of unknown etiology, characterized by the accumulation of proteinoceous material in the alveoli that is rich in lipid and is positive on periodic acid-Schiff (PAS) stain.2–4 Although its exact pathogenesis is unclear, most investigators have postulated a decreased clearance of surfactant from the air spaces.45 PAP is rare in children, with only a few dozen cases reported in the literature.2 Today, PAP can be categorized in to three different classes: congenital, acquired, and secondary to other conditions, such as malignancy (i.e. leukemia and lymphoma) and immunodeficiency.67 Two forms are encountered in pediatric practice: congenital alveolar proteinosis (CAP) and a later-onset form that is generally less severe. These 2 types differ in respect to etiology, clinical course, therapy and outcome.3 Family history of a similarly affected sibling or consanguinity suggests autosomal recessive transmission.2 The later-onset form always appears after a postnatal, symptom-free period ranging from a few weeks to several years. The main symptoms are non-specific, including progressive onset dyspnea during feeding or exercise and then at rest, cough, cyanosis and digital clubbing. Asthenia and growth retardation are common. The progression of the disease is very variable, ranging from asymptomatic forms diagnosed by chance to earlyonset forms that progress rapidly and result in uncontrollable respiratory failure.28 The classic radiologic appearance of PAP is bilateral, symmetric, perihilar airspace consolidation in a bat-wing distribution.3 The diagnosis of postnatal onset pediatric PAP is based on examination of the BAL sample and/or lung biopsy.2 Broncho-alveolar lavage is the key to diagnosis.259 The most effective treatment for PAP is the mechanical removal of the proteinaceous material via whole lung lavage (WLL)10–12 which was initially proposed by Ramirez in 1965, this method is still the only therapy that is really effective. Other therapeutic trials have been proposed such as: lung transplantation, adminstration of GM-CSF and gene-therapy.2313 This report describes eight cases of PAP which were diagnosed by open lung biopsy in Mofid Children Hospital in Tehran.

Case Report

The main characteristics of patients are presented in table 1. The median presentation age was 2.4 years, (6 mo-5 yr). Consanguinity was found in five patients.
Table 1

The main characteristics of seven children with PAP, Mofid Children Hospital, Tehran

NoGenderAge of onsetAge of DxMain symptomsMain signsConsanguinityHemoglubinPaO2mm HgRadiologic findingsDx toolsTreatmentLast follow up after DxOutcome
1F2.5 y3 yDry cough fever FTT*Tachypnea/fine rales+15.545.8Diffuse alveolar infiltratesOLB***GM-CSF9 moExpired at home
2F2.5 y4.5 yDry cough FTT exercise intoleranceRD** diminished breath-soundschest muscle retraction+10.249Diffuse alveolar infiltrates/airbroncho gramOLBWLL†† × 2 with CPB†††8 moExpired due to pulmonary hemorrhage after lavage
3M3 y4 yDry cough cyanotic attacks anorexia exercise intoleranceRD diffuse crackles/ sys heart murmur12.360Diffuse alveolar infiltrates/airbroncho gram/hilar adenopathyOLBWLL × 2 with CPB15 moExpired at home
4M3.5 y4 yDry cough cyanosis exercise intoleranceCyanosis RD diffuse crackles+1250.5Diffuse alveolar infiltrates/airbroncho gramOLBGM-CSF / segmentai & WLL with CPB & ECMO §36 moO2 DEP§§ alive
5M6 mo6 monDry cough poor feeding exercise intoleranceDiffuse crackles RD chest muscle retraction8.961.9Diffuse alveolar infiltrates/ground glass appearanceOLBAntibiotics + O2 therapy1 moExpired after OLB
6M2.5 y4 ySevere cyanosis progressive apnea exercise intoleranceSevere cyanosis RD respiratory arrest+12Diffuse alveolar infiltratesOLBO2 therapy/WLL × 2 with CPB36 moFree of O2alive
7F4 y5 yDry cough anorexia FTT exercise intoleranceTachypnea RD rales on left lungUN1160 withDiffuse alveolar infiltrates/hilar adenopathyOLBWLL × 36 moExpired after third lavage
8F1 y1 yFTT cough cyanosisTachypnea RD+14.452Diffuse alveolar infiltrates/ air bronchogramOLB1 yExpired due to RD after OLB

FTT: Failure to thrive;

RD: Respiratory distress;

OLB: Open lung biopsy;

GM-CSF: Granulocyte macrophage colony stimulating factor;

WLL: Whole lung lavage;

CPB: Cardio pulmonary bypass;

ECMO: Extracorporeal membrane oxygenation;

O2 DEP: Oxygen dependent

The main characteristics of seven children with PAP, Mofid Children Hospital, Tehran FTT: Failure to thrive; RD: Respiratory distress; OLB: Open lung biopsy; GM-CSF: Granulocyte macrophage colony stimulating factor; WLL: Whole lung lavage; CPB: Cardio pulmonary bypass; ECMO: Extracorporeal membrane oxygenation; O2 DEP: Oxygen dependent The main presenting symptoms were growth retardation, exercise intolerance, cough, progressive dyspnea and oxygen dependency. Chest X-ray revealed diffuse alveolar infiltration in seven children with an air bronchogram in four (Figure 1). Echocardiography revealed no anatomical shunt but RA and RV dilatation, TR, dilated PA and high cardiac output were noted in 5 patients. Echocardiography was normal in two children. Chest CT scan was done in three patients, which showed diffuse interstitial and alveolar infiltration (Figure 2). Open lung biopsy (OLB) confirmed the diagnosis in all children. Figure 3 shows the pathologic feature of case no. 6. Secondary causes of PAP were ruled out by history taking and lab tests but checking anti-GMCSF antibody or gene mutation were unavailable.
Figure 1

Chest X-ray of pulmonary alveolar proteinosis in patient no. 4

Figure 2

Chest CT-scan of patient no. 4 with pulmonary alveolar proteinosis

Figure 3

Pathologic feature of PAP in patient no. 6: presence of marked diffused intraalveolar pinkish deposition; positive with PAS staining. Serial sections were reviewed and no inflammatory infiltrate, parasite and fungi were identified.

Chest X-ray of pulmonary alveolar proteinosis in patient no. 4 Chest CT-scan of patient no. 4 with pulmonary alveolar proteinosis Pathologic feature of PAP in patient no. 6: presence of marked diffused intraalveolar pinkish deposition; positive with PAS staining. Serial sections were reviewed and no inflammatory infiltrate, parasite and fungi were identified. For two first patients GM-CSF was started subcutaneously because WLL was not practically available in present setting at first. First patient received it for 3 months, and the parents didn’t continue it, and she died after 6 months. For the second patient (case no. 4) GMCSF was used for 2 months. The response monitoring was done by clinic (cyanosis, respiratory rate, activity, and well-being), oxygenation (SpO2and ABG) and X-ray. None of these changed during the administration of GMCSF. Lobar or segmental lavage by fiberoptic bronchoscope is useful when PAP is less advanced or general anesthesia is hazardous.4 This method could be done in most hospitals and proteinaceous fluid can be removed with a small volume of saline.4 The segmental lung lavage was tried for PAP with fiberoptic bronchoscope. Only 1-2 segments in each procedure could be lavaged. It was repeated for 3 times and it was partially effective. Therapeutic whole lung lavage (WLL) is carried out under general anesthesia and each time one lung, lobe or segment is washed with normal saline24; finally both lungs were washed while patients were on CPB; using ECMO didn’t facilitate the WLL. The procedure was done in five patients and due to recurrence, repeated WLL was necessary in 4 patients. Two patients with WLL are alive after 5 years, and one of them is free of oxygen. Six patients died, one due to pulmonary hemorrhage during WLL and five within 0.5-15 months after the diagnosis due to severe respiratory failure.

Discussion

Clinical presentation with cough and progressive dyspnea in present cases was compatible with other case series1–16; though, chest pain, hemoptysis, fever and weight loss have also been reported.51517 Due to the rarity of PAP, non-specific signs and symptoms, variability in severity and course, and the fact that it may be asymptomatic in up to 30% of cases, the diagnosis can be easily delayed or missed.58 There was an average of 9.7 month delay between presentation and diagnosis in present patients. The radiologic findings in present patients showing diffuse alveolar infiltration were consistent with prior studies, although interstitial and nodular patterns have been reported.315 Although BAL examination can be sufficient for diagnosis of PAP in adults, but in children, the histopathologic examination of open transthorasic or transbronchial lung biopsy is the gold standard for diagnosis.4 Unfortunately checking anti-GMCSF antibody and measuring surfactant protein B were unavailable, and to rule out other similar diseases open lung biopsy was preferred to confirm PAP. In this study, time from beginning of clinical manifestations to diagnosis was approximately 11 months; this delay may be due to non-specific clinical and radiological findings, variable progression course and physician’s unfamiliarity with the disease. Although administration of GM-CSF may improve pulmonary function in adults and it may be effective in children, the first 2 patients who took it empirically did not improve.9 It is believed that mechanical removal of proteinaceous material (WLL) by an expert team may be the most suitable therapy in Iran especially in children, as it improved the clinical course in four out of five of patients. Because the natural course of the disease may be recurrent, WLL may be needed repeatedly. In a pediatric case study the WLL patients did well,18 but 3 of present cases died, one during the procedure due to pulmonary hemorrhage and 2 succumbed after repeated WLL due to recurrence. Mortality rate was 75% in present cases, similar to other reports with the duration of illness ranging from a few days to several months. The mortality of congenital PAP is 100% without lung transplantation.3 Late-onset disease has better prognosis, but repeated lung lavage is generally required. It is believed that the poor prognosis in present patients is due to delay in diagnosis, severity of disease, non-compliance of family for recurrent WLL and in a few patients, lack of close team collaboration.

Conclusions

In conclusion, the authors emphasize that missed and delayed diagnosis could be avoided by physicians’ awareness of PAP; diagnosis of postnatal onset PAP should be considered in every patient with respiratory distress or failure with diffuse interstitial and alveolar infiltration. Examination of the BAL sample and/or a lung biopsy is the key to diagnosis and atypical specimens should be approached with caution which may represent either PAP or other pulmonary diseases with secondary accumulation of surfactant WLL could be the most suitable treatment for late-onset PAP in Iran.
  13 in total

1.  Pulmonary alveolar proteinosis: a pediatric case study.

Authors:  C T Thompson; P A Tirone
Journal:  Pediatr Nurs       Date:  2000 Nov-Dec

2.  Pulmonary alveolar proteinosis.

Authors:  S H ROSEN; B CASTLEMAN; A A LIEBOW
Journal:  N Engl J Med       Date:  1958-06-05       Impact factor: 91.245

Review 3.  Pulmonary alveolar proteinosis in children.

Authors:  Jacques de Blic
Journal:  Paediatr Respir Rev       Date:  2004-12       Impact factor: 2.726

4.  Pulmonary alveolar proteinosis: a report of seven patients from King Chulalongkorn Memorial Hospital.

Authors:  Kamon Kawkitinarong; Chanchai Sittipunt; Somkiat Wongtim; Visit Udompanich
Journal:  J Med Assoc Thai       Date:  2005-09

5.  CT features of pulmonary alveolar proteinosis.

Authors:  J M Holbert; P Costello; W Li; R M Hoffman; R M Rogers
Journal:  AJR Am J Roentgenol       Date:  2001-05       Impact factor: 3.959

6.  Pulmonary Alveolar Proteinosis: recent advances.

Authors:  Peter J Mazzone; Mary Jane Thomassen; Mani S Kavuru
Journal:  Semin Respir Crit Care Med       Date:  2002-04       Impact factor: 3.119

7.  Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years.

Authors:  K Kariman; J A Kylstra; A Spock
Journal:  Lung       Date:  1984       Impact factor: 2.584

8.  Pulmonary alveolar proteinosis: treatment by bronchofiberscopic lobar lavage.

Authors:  Shih-Lung Cheng; Hou-Tai Chang; Hon-Ping Lau; Li-Na Lee; Pan-Chyr Yang
Journal:  Chest       Date:  2002-10       Impact factor: 9.410

9.  Alveolar proteinosis: diagnosis and treatment over a 10-year period.

Authors:  R M Du Bois; W A McAllister; M A Branthwaite
Journal:  Thorax       Date:  1983-05       Impact factor: 9.139

10.  Physiologic effects of bronchopulmonary lavage in alveolar proteinosis.

Authors:  R M Rogers; D C Levin; B A Gray; L W Moseley
Journal:  Am Rev Respir Dis       Date:  1978-08
View more
  4 in total

Review 1.  Metabolic Functions of the Lung, Disorders and Associated Pathologies.

Authors:  Alcibey Alvarado; Isabel Arce
Journal:  J Clin Med Res       Date:  2016-08-30

2.  Pulmonary alveolar proteinosis: a case report and world literature review.

Authors:  Armando J Huaringa; Wassem H Francis
Journal:  Respirol Case Rep       Date:  2016-11-13

3.  Whole-Genome Sequencing of a Family with Hereditary Pulmonary Alveolar Proteinosis Identifies a Rare Structural Variant Involving CSF2RA/CRLF2/IL3RA Gene Disruption.

Authors:  Chih-Yung Chiu; Shih-Chi Su; Wen-Lang Fan; Shen-Hao Lai; Ming-Han Tsai; Shih-Hsiang Chen; Kin-Sun Wong; Wen-Hung Chung
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

4.  Whole lung lavage of nine children with pulmonary alveolar proteinosis: experience in a tertiary lung center.

Authors:  Radpay Badiozaman; Parsa Tahereh; Dabir Shideh; Boloursaz Mohammadreza; Arbab Ahmadreza; Tabatabaei Seyyedahmad
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.